Sarepta Therapeutics saw its stock skid 11% after the company announced preliminary unaudited 2025 sales results that missed analyst forecasts for its marketed Elevidys® (delandistrogene ...
Advantage Energy benefits from La Niña cold, rising natural gas demand, new well returns, and potential rig restarts. Read ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback